Rationale and Comments

The main identifiable risk associated with reducing or discontinuing acid suppression therapy is an increased symptom burden. It follows that the decision regarding the need for (and dosage of) maintenance therapy is driven by the impact of those residual symptoms on the patient’s quality of life rather than as a disease control measure.

Sponsoring Organizations

• American Gastroenterological Association

Sources

• American Gastroenterological Association position statement

Disciplines

• Gastroenterologic

References

• Kahrilas PJ, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383-91.